The Neuroendocrine Tumor Research Foundation’s (NETRF) mission is to discover cures and more effective treatments for carcinoid, pancreatic neuroendocrine and other forms of neuroendocrine cancers.
NETRF is the leading non-profit organization funding neuroendocrine cancer research, having awarded more than twelve million dollars in research grants since its founding in 2005. Our approach is to award research grants to physicians and scientists whose work will provide insight into the causes of neuroendocrine tumors and/or lead to improved treatment for patients who suffer from these cancers. Although we have made significant inroads, we still have limited resources, too few neuroendocrine tumor investigators and an inadequate understanding of the unique characteristics of these tumors that could point the way to better diagnostic approaches, treatments and cures for patients.
NETRF is launching a new Accelerator Program specifically designed to fund research with the potential to transform our understanding of neuroendocrine cancers and/or have substantial promise to lead to improved treatments and diagnostics for patients. The generous support of our donors and family foundation partners –most recently the generous gift of the Margie and Robert E. Petersen Foundation- provides us with the opportunity to offer these larger, multi-year grants in the hope that we can attract the very best investigators and the most promising ideas to rapidly advance knowledge in our pursuit of cures.
Specifically, we are seeking investigators and teams with the tools to study neuroendocrine tumor biology in creative, sustained ways that have heretofore not been pursued. We are open to proposals from a broad array of disciplines including but not limited to investigations in genetic and epigenetic profiling, intensive analysis of cell biology and protein expression, immune microenvironment of tumors, development of faithful disease models or any other area with an impact on the biology of neuroendocrine tumors.
NETRF is accepting proposals from individuals and/or teams for four-year grants of $300,000 per year. Applications will be reviewed by the NETRF Board of Scientific Advisors (BOSA) and outside reviewers as recommended by BOSA. The NETRF BOSA will make recommendations to the Board of Directors, which has final approval of funding.
Letters of intent are due by October 14, 2016, with full applications due by November 18, 2016. Funding for approved projects will begin in early 2017.
Additional details and instructions for submission follow in this document.
NETRF welcomes all proposals with potential for impact on our understanding of these cancers and development of diagnostic and therapeutic interventions for patients, including but not limited to these areas:
- Studies built on the significance and potential impact of mutations in NETs including DAXX/ATRX, MEN1 or CDKN1B.
- Genetic and epigenetic mechanisms of NETs.
- Neuroendocrine-specific organoids or other model systems and collaborative work to use these models to explore novel therapeutics.
- Investigations into synthetic lethality for neuroendocrine tumor cells.
- Proteomic approaches to identifying novel epitopes that may be used for immunotherapy and other therapeutic modalities.
- Antibody or other approaches to target tumor cells.
Proposals which cover mechanisms from other areas of cancer research not specific to neuroendocrine tumors will be evaluated based on the level of applicability to neuroendocrine tumors.
In summary, while the areas noted here are of particular interest to our Scientific Advisors, we are open to any projects with the potential to make a transformative contribution to our understanding of these cancers and development of diagnostic and therapeutic interventions for patients.
We encourage applications from all sources including: individuals, individuals in the first five years of a research career, multidisciplinary or multi-institutional teams. For team applications, a Recipient Principal Investigator and Recipient Institution must be selected.
International applications welcome. Grants will be paid in US dollars.
- Applicants must spend the majority of effort in clinical investigation or basic research.
- MD, PhD, MD/PhD or equivalent degree required.
- Candidates must demonstrate a commitment to neuroendocrine tumor research and the potential for further development in this area. Please note that prior research in this field is not a prerequisite; in fact, the Foundation wishes to encourage expert scientists to enter the field. Applicants must, however, demonstrate their commitment to continue with outstanding research in the area of neuroendocrine tumors beyond the award period.
- Investigators must agree to present updated progress twice per year including at the annual NETRF research symposium held in the spring each year. Information on mutually convenient dates and locations will be identified by NETRF.
- A progress report summarizing research accomplishments and use of the funds is required biannually for the duration of the award on June 30 and December 31. Future funding will be contingent upon review of progress and achievement of relevant milestones.
Individuals or Teams are invited to submit four-year proposals for up to $300,000 per year. The total budget request may not exceed $1,200,000.
- NETRF expects to award at least one grant in the first year.
- Awarded funds are directed to the institution.
- Funds may be used for personnel salaries, supplies, small equipment, and/or research-related services only. Funds must not be used entirely for salaries.
- Up to 10% in indirect costs may be requested.
- Funds may not be applied to costs covered by other sources.
- Funds may be used to attend meetings as mandated in the grant.
The Peer Review Committee for these grants is the Neuroendocrine Tumor Research Foundation’s Board of Scientific Advisors (BOSA) and additional outside experts, as needed. Members of the Peer Review Committee will be recused if investigators from their institutions submit an Application or if there is another direct or perceived conflict of interest.Applicants may make reasonable requests that a member of the Peer Review Committee not review their Application.
NETRF’s Peer Review Committee will evaluate all Applications against five criteria, in accordance with NIH guidelines:
A statement of institutional commitment, including any tangible support that the institution is willing to commit to the project, while not required, will be considered as an additional factor in the review of applications for funding.
NETRF’s Board of Directors, acting in its sole discretion, will select the research grant recipients based on the recommendations of the Peer Review Committee, funds available, and impact of the research on the mission of the Neuroendocrine Tumor Research Foundation.
The application contains two parts, a Letter of Intent and the body of the proposal (“General Proposal”).
Letter of Intent
The purpose of the Letter of Intent is to inform NETRF of the areas of inquiry of the incoming proposals to allow for appropriate development of review panels. All Letters of Intent will be considered for a full proposal. This letter must contain:
- Proposed title
- Brief description of the proposed study including hypothesis and potential outcomes
- Principal investigator and team members. If multiple Co-Principal Investigators are desired, designate a recipient institution and a recipient Principal Investigator at this institution. The Recipient Institution will be the Sponsoring Institution.
This Letter of Intent is due on October 14, 2016 by 5 pm Eastern Standard Time, US, by electronic mail to firstname.lastname@example.org. Limit of 2 pages.
Please do not exceed 8 pages for the body of the proposal, using single-spaced, 12-point Times New Roman font. The proposal must include all figures, charts, tables, and preliminary data. Other required elements are:
- Principal Investigator (or Co-Principal Investigators) name, title, and contact information
- Address, Telephone, Fax, and E-mail
- Sponsoring Institution (in the case of Co-Principal Investigators, Recipient Institution) name and contact information
- Address, Telephone, Fax, and E-mail
- Description of project
- Objectives, as they relate to the goals of the NETRF mission
- Abstract (scientific version)
- Abstract (lay version)
- Performance metrics to track rapid progress
- List and roles of all involved personnel and collaborators
- Funding requested
- Duration requested
- Detailed research proposal (NIH format)
- Specific aims
- Approach, including plan for access to any necessary patient tumor samples
- Detailed budget, including other sources of support
- Plan for sharing research data and resources with other scientists/institutions
Applicants should include these elements in an Appendix, for which there is no page limit.
- Biosketch (NIH format) of the Principal Investigator and key collaborators
- List of all sources of funding (current and pending) for the Principal Investigator, including the specific aims associated with each source
- Optional: Reprints and/or letters of collaboration
Sign and date the following statement on a separate page (does not count toward page limits):
“I certify that the statements herein are true, complete, and accurate to the best of my knowledge. Any false or fraudulent statements or claims may subject me to criminal, civil, and/or administrative penalties. I have read and agree to be bound by the Neuroendocrine Tumor Research Foundation’s Research Grant Policies and Procedures.”
Department Chairperson (or equivalent) of the applicant’s Sponsoring Institution must sign and date the following statement on a separate page (does not count toward page limits):
“I certify that the statements herein are true, complete, and accurate to the best of my knowledge. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, and/or administrative penalties. [Insert name of Sponsoring Institution] has read and agrees to be bound by the Neuroendocrine Tumor Research Foundation’s Research Grant Policies and Procedures.”
- Deadline for Submission is November 18, 2016
- Application must conform to the prescribed page limits.
- Application cannot be changed after submission.
- Convert the Application to a single PDF file and email to email@example.com. Please use Accelerator Program Proposal in your email subject line.
- The Neuroendocrine Tumor Research Foundation will e-mail applicants to confirm receipt of the Application within 5 business days.
- Applications cannot be changed after submission. Incomplete applications will not be reviewed.
- The Neuroendocrine Tumor Research Foundation will disclose the Application only to individuals directly involved in our process to award research grants.
The deadline for submission of proposals is November 18, 2016 at 5pm, Eastern Time.
For any questions about the application and selection process, please contact firstname.lastname@example.org.